Home About us Contact
|
Home About us Contact | ||
|
|
||
Faecal Excretion (faecal + excretion)
Selected AbstractsMorphine or its withdrawal affects plasma malondialdehyde, vitamin E levels and absence or presence of abstinence signs in ratsJOURNAL OF PHARMACY AND PHARMACOLOGY: AN INTERNATI ONAL JOURNAL OF PHARMACEUTICAL SCIENCE, Issue 4 2009Professor Arnaldo Pinelli Abstract Objectives Various experimental observations show that morphine treatment generates reactive oxygen species, and that its discontinuation leads to signs of withdrawal. We therefore investigated plasma malondialdehyde and vitamin E levels under both conditions to verify the occurrence of any alterations in oxidative metabolism, and whether these are associated with behavioural changes. Methods We investigated the effects of morphine or morphine plus naloxone on plasma malondialdehyde, vitamin E levels and withdrawal signs such as jumping, wet dog shakes and faecal excretion in rats. Furthermore, isopropylnoradrenaline was injected in rabbits to verify its effects on plasma malondialdehyde levels. Key findings Morphine treatment increased free malondialdehyde and decreased vitamin E levels. The elevation in malondialdehyde levels were exacerbated by the abrupt removal of morphine by naloxone, which also led to the appearance of withdrawal signs. The increased malondialdehyde values can be attributed to the interactions of reactive oxygen species with unsaturated fatty acids, and the lowered levels of vitamin E to its interactions with reactive oxygen species. Conclusions A connection seems to exist between altered peroxide status and withdrawal signs in abstinent animals. [source] The behaviour of doramectin in the gastrointestinal tract, its secretion in bile and pharmacokinetic disposition in the peripheral circulation after oral and intravenous administration to sheepJOURNAL OF VETERINARY PHARMACOLOGY & THERAPEUTICS, Issue 4 2000D. R. HENNESSY Sheep were ,compartmentalized' by surgically implanting cannulae in the rumen, abomasum and terminal ileum with a re-entrant cannula inserted between the cystic duct and the duodenum to monitor bile secretion. Doramectin, containing a trace of [3H]-doramectin, was administered both intravenously (i.v.) and intraruminally (i.r.) at a dosage of 150 ,g/kg. The pharmacokinetic behaviour of [3H]-labelled products was determined in these pools, and also in peripheral plasma, urine and faeces. Parent doramectin was also determined in plasma, abomasal digesta fluid and bile. Following i.r. administration, [3H] compounds were almost entirely associated with particulate digesta. A 14.5-h half-life in the rumen prolonged the presence of [3H] in the abomasum. Doramectin appeared to be degraded in abomasal digesta because only 24% of abomasal [3H] was attributed to the parent drug. Absorption of doramectin resulted in a systemic availability of 35%, of which 1.6 and 23.6% of the dose was contained in urine and biliary secretions, respectively. Following i.v. administration, almost negligible quantities of [3H] were secreted into the rumen or abomasum and only 2.7% of the dose was excreted in urine, whereas 132% was secreted in bile. This indicated that approximately one-third of biliary metabolites were enterohepatically recycled with biliary metabolites, elevating the proportion of [3H] in fluid digesta in the small intestine. Passage of the IR-administered drug through the gastrointestinal tract (GIT) resulted in virtually complete faecal excretion of [3H] within 5 days, whereas the continued secretion of i.v.-administered [3H] in bile prolonged the presence of [3H] in the GIT, with faecal clearance not being complete for at least 10 days. This multi-compartmental study has provided more information on the behaviour of doramectin than can be obtained from examining drug disposition in the peripheral circulation alone. With this knowledge, it is anticipated that opportunities for improving drug performance will be identified. [source] Estimate of the sensitivity of an ELISA used to detect Johne's disease in Victorian dairy cattle herdsAUSTRALIAN VETERINARY JOURNAL, Issue 9 2004TF JUBB Objective To estimate the sensitivity of the ELISA used in dairy cattle herds participating in the Victorian Bovine Johne's Disease Test and Control Program (TCP). Procedure The percentage of ELISA reactors in age and test cohorts was estimated from age-specific test data derived from TCP herds with long testing histories. Age-distribution data from production-tested herds enabled estimation of reactor rates in animals that were culled or died. Results ELISA sensitivities at the first test round in herds achieving five, six and seven annual herd tests were 16.1, 14.9 and 13.5% respectively. The ELISA sensitivity in 2, 3 and 4-year-old animals at the first test round in herds testing seven times was 1.2, 8.9 and 11.6% respectively but remained between 20 and 30% in older age-groups. Conclusion The sensitivity of the ELISA is considerably lower than previous estimates, probably because previous estimates were predominantly measured against faecal culture, which has subsequently been shown to have low sensitivity itself, and did not appreciate the long period that appears to precede detectable faecal excretion in most animals. [source] Prolonged faecal excretion following a single dose of probiotic in low birth weight infantsACTA PAEDIATRICA, Issue 10 2010Richard Mc Gee No abstract is available for this article. [source] Increasing antimicrobial resistance,an emerging problem in the treatment of shigellosisCLINICAL MICROBIOLOGY AND INFECTION, Issue 12 2007S. K. Niyogi Abstract Shigellosis is a major cause of diarrhoea-related morbidity and mortality, especially in developing countries. Effective antibiotic treatment reduces the average duration of illness by reducing faecal excretion of the bacterium and preventing further transmission and potentially lethal complications. Treatment of shigellosis is currently limited by the high prevalence of multidrug-resistant strains of Shigella. Although fluoroquinolones are currently effective in treating adults, resistance to fluoroquinolones among Shigella spp. is emerging, and their use in children is subject to limitations. Azithromycin and third-generation cephalosporins are also effective in the treatment of shigellosis, but monitoring of Shigella isolates to detect the emergence of resistance is essential. [source] | ||||||||||